<a href="https://www.fiercebiotech.com/biotech/regenxbio-reaps-pivotal-win-duchenne-muscular-dystrophy-gene-therapy" hreflang="en">Regenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapy</a>
fiercebiotech.com·May 14, 2026
Regenxbio's gene therapy for Duchenne muscular dystrophy has successfully met the primary endpoint of its pivotal trial, marking a significant achievement for the company following recent setbacks, including an FDA rejection and clinical hold.
For a professional tracking healthtech and biotech, the successful pivotal trial of Regenxbio’s gene therapy for Duchenne muscular dystrophy underscores the potential for gene therapies to overcome regulatory setbacks and achieve significant clinical milestones. This highlights the importance of monitoring companies with resilient R&D pipelines, as they can rebound and deliver impactful innovations despite previous regulatory challenges.